← United States · Coverage record
US · SEC FORM 4
Opus Genetics, Inc.
IRD · Nasdaq · CIK 0001228627 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
16 Form 4 transaction lines observed in the same window
13 sales · 3 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-29 · Gallagher Cam.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 13,013,222
- Previous report
- 12,578,772
- Avg daily volume
- 2,150,972
- Days to cover
- 6.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | Gallagher Cam | Purchase (P) | Common Stock | 164,000 | USD 1.97 | USD 323,890 | SEC filing ↗ |
| 2024-12-26 | Magrath George | Purchase (P) | Common Stock | 100,000 | USD 0.98 | USD 98,000 | SEC filing ↗ |
| 2024-11-21 | YERXA BENJAMIN R | Purchase (P) | Common Stock | 10,000 | USD 0.98 | USD 9,800 | SEC filing ↗ |
| 2024-11-18 | Magrath George | Purchase (P) | Common Stock | 9,706 | USD 1.02 | USD 9,900 | SEC filing ↗ |
| 2024-11-15 | Magrath George | Purchase (P) | Common Stock | 90,294 | USD 1.01 | USD 91,197 | SEC filing ↗ |
| 2024-05-22 | Jayagopal Ashwath | Purchase (P) | Common Stock | 3,500 | USD 1.77 | USD 6,195 | SEC filing ↗ |
| 2024-05-17 | Magrath George | Purchase (P) | Common Stock | 5,000 | USD 1.75 | USD 8,750 | SEC filing ↗ |
| 2024-03-21 | SCHACHLE JOSEPH K | Purchase (P) | Common Stock | 2,000 | USD 2.05 | USD 4,100 | SEC filing ↗ |
| 2024-03-21 | Jhaveri Nirav S. | Purchase (P) | Common Stock | 10,000 | USD 2.10 | USD 21,000 | SEC filing ↗ |
| 2024-03-18 | Magrath George | Purchase (P) | Common Stock | 25,000 | USD 1.96 | USD 49,000 | SEC filing ↗ |
| 2022-05-20 | MANUSO JAMES S J | Purchase (P) | Common Stock | 5,000 | USD 1.99 | USD 9,950 | SEC filing ↗ |
| 2022-05-20 | Sooch Mina | Purchase (P) | Common Stock | 12,500 | USD 2.02 | USD 25,250 | SEC filing ↗ |
| 2022-05-19 | Sooch Mina | Purchase (P) | Common Stock | 12,500 | USD 2.07 | USD 25,875 | SEC filing ↗ |
| 2021-12-13 | Pepose Jay | Purchase (P) | Common Stock | 8,250 | USD 3.65 | USD 30,112 | SEC filing ↗ |
| 2021-11-18 | MANUSO JAMES S J | Purchase (P) | Common Stock | 2,000 | USD 3.50 | USD 7,000 | SEC filing ↗ |
Form 4 evidence
48 transaction lines in the latest 365-day window; 171 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | Sale (S) | Common Stock | 556,000 | USD 4.96 | USD 2,755,981 | SEC filing ↗ |
| 2026-09-09 | Magrath George | Option exercise / conversion (M) | Common Stock | 392,157 | USD 1.15 | USD 450,981 | SEC filing ↗ |
| 2026-09-09 | Magrath George | Tax withholding (F) | Common Stock | 75,541 | USD 5.97 | USD 450,980 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | Sale (S) | Common Stock | 556,000 | USD 4.96 | USD 2,755,981 | SEC filing ↗ |
| 2026-09-09 | Magrath George | Option exercise / conversion (M) | Common Stock | 392,157 | USD 1.15 | USD 450,981 | SEC filing ↗ |
| 2026-09-09 | Magrath George | Tax withholding (F) | Common Stock | 75,541 | USD 5.97 | USD 450,980 | SEC filing ↗ |
| 2026-09-08 | Gallagher Cam | Option exercise / conversion (M) | Common Stock | 784,314 | USD 1.15 | USD 901,961 | SEC filing ↗ |
| 2026-09-03 | Gagnon Robert E. | Sale (S) | Common Stock | 28,000 | USD 4.54 | USD 127,120 | SEC filing ↗ |
| 2026-07-23 | YERXA BENJAMIN R | Sale (S) | Common Stock | 7,429 | USD 2.97 | USD 22,064 | SEC filing ↗ |
| 2026-07-23 | SCHACHLE JOSEPH K | Sale (S) | Common Stock | 4,644 | USD 2.94 | USD 13,653 | SEC filing ↗ |
| 2026-07-23 | Magrath George | Sale (S) | Common Stock | 9,475 | USD 2.95 | USD 27,951 | SEC filing ↗ |
| 2026-07-23 | Gagnon Robert E. | Sale (S) | Common Stock | 7,783 | USD 2.95 | USD 22,960 | SEC filing ↗ |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | Sale (S) | Common Stock | 1,700,000 | USD 4.35 | USD 7,395,000 | SEC filing ↗ |
| 2026-04-23 | Zaremba Rabourn Amy | Sale (S) | Common Stock | 1,641 | USD 5.20 | USD 8,533 | SEC filing ↗ |
| 2026-04-23 | YERXA BENJAMIN R | Sale (S) | Common Stock | 7,470 | USD 5.24 | USD 39,143 | SEC filing ↗ |
| 2026-04-23 | SCHACHLE JOSEPH K | Sale (S) | Common Stock | 4,697 | USD 5.22 | USD 24,518 | SEC filing ↗ |
| 2026-04-23 | Magrath George | Sale (S) | Common Stock | 9,511 | USD 5.22 | USD 49,647 | SEC filing ↗ |
| 2026-04-23 | Jayagopal Ashwath | Sale (S) | Common Stock | 7,542 | USD 5.19 | USD 39,143 | SEC filing ↗ |
| 2026-04-23 | Gagnon Robert E. | Sale (S) | Common Stock | 7,842 | USD 5.18 | USD 40,622 | SEC filing ↗ |
| 2026-04-20 | Rodgers Richard J | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | MANUSO JAMES S J | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Graves Adrienne L | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Gallagher Cam | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Benton Susan | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Bennett Jean | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-04-20 | Ainsworth Sean | Award / grant (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-16 | Zaremba Rabourn Amy | Sale (S) | Common Stock | 2,816 | USD 5.25 | USD 14,784 | SEC filing ↗ |
| 2026-03-16 | SCHACHLE JOSEPH K | Sale (S) | Common Stock | 3,719 | USD 5.25 | USD 19,525 | SEC filing ↗ |
| 2026-03-16 | Magrath George | Sale (S) | Common Stock | 24,438 | USD 5.21 | USD 127,322 | SEC filing ↗ |
| 2026-03-16 | Jayagopal Ashwath | Sale (S) | Common Stock | 3,719 | USD 5.12 | USD 19,041 | SEC filing ↗ |
| 2026-02-12 | Jayagopal Ashwath | Tax withholding (F) | Common Stock | 5,313 | USD 3.39 | USD 18,011 | SEC filing ↗ |
| 2026-01-22 | Zaremba Rabourn Amy | Award / grant (A) | Common Stock | 86,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-22 | YERXA BENJAMIN R | Award / grant (A) | Common Stock | 400,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | IRD |
| CIK | 0001228627 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 171 transaction lines from 2020-11-05 to 2026-09-30 24 P purchase lines · 18 S sale lines · 129 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.